Progyny (PGNY) Financials, Dividends & Stock Info
Explore comprehensive financial data for Progyny, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (546 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Progyny (PGNY) is a health care services company. The company reports annual revenue of $1.2B and net income of $54M. Its profit margin is 4.7%.
Progyny Key Financials
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Progyny Financial Health ScoreFY2025
Good overall health with some areas for improvement
+1 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
About Progyny
- Industry
- Health Care Services
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin Marginsvs 4.1% sector median / 2.3% avg
Keeps 5 cents of every dollar in revenue as profit. Higher than 55% in Health Care.
5th consecutive year of revenue growth.
Profit margin 106% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
Progyny 9-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2017| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B(+10.4%) | $1.2B(+7.2%) | $1.1B(+38.3%) | $786.9M(+57.2%) | $500.6M(+45.2%) | $344.9M | - | - | - |
| Net Income | $58.5M(+7.7%) | $54.3M(-12.4%) | $62.0M(+104.4%) | $30.4M(-53.8%) | $65.8M(+41.6%) | $46.5M(+642.2%) | $-8,569,000(-1396.4%) | $661,000(+105.3%) | $-12,452,000 |
| Total Assets | $742.4M | $607.1M | $756.6M | $543.0M | $358.1M | $253.9M | $150.4M | $41.3M | - |
| Total Debt | - | - | - | - | - | - | - | - | - |
| Total Equity | $516.0M | $422.1M | $553.4M | $377.0M | $251.8M | $166.9M | $114.3M | $-95,115,000 | $-97,622,000 |
| Profit Margin | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | - | - | - |
| ROE | 11.3% | 12.9% | 11.2% | 8.1% | 26.1% | 27.8% | -7.5% | - | - |
| ROA | 7.9% | 8.9% | 8.2% | 5.6% | 18.4% | 18.3% | -5.7% | 1.6% | - |
Quarterly Financials
Last 8 quarters| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Net Income | - | - | $15.1M | - | - | $16.9M | - | - |
| Total Assets | $795.2M | $761.0M | $730.3M | $660.0M | $698.6M | $794.3M | $726.5M | $681.5M |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Progyny Free Cash Flow & Dividend Coverage
Cash Flow History
FY2017 - FY2025| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$9.5M | $2.3M | -$1.5M | $36.2M | $26.0M | $80.4M | $188.8M | $179.1M | $210.2M |
| CapEx | -$612,000 | -$579,000 | -$3.0M | -$1.0M | -$2.1M | -$3.2M | -$3.6M | -$5.4M | -$18.4M |
| Free Cash Flow | -$10.1M | $1.7M | -$4.5M | $35.2M | $23.9M | $77.2M | $185.2M | $173.7M | $191.8M |
| FCF Margin | - | - | - | 10.2% | 4.8% | 9.8% | 17.0% | 14.9% | 14.9% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
Progyny Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for PGNY.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Progyny FAQ
What is Progyny's annual revenue?
Progyny (PGNY) reported $1.2 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Progyny profitable?
Yes, Progyny is profitable with a 4.7% net profit margin and $54 million in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Progyny pay dividends?
No, Progyny (PGNY) does not currently pay dividends to shareholders.
What is Progyny's financial health score?
Progyny has a financial health score of 75/100 (Grade: B), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Progyny financial data are available?
9 years of financial data are available for Progyny from FY2017 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.